Company profile for Jiangsu Gensciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Gensciences has submitted an NDA for its recombinant coagulation factor VIII-Fc fusion protein, advancing our mission to provide ?zero-bleeding? treatment for hemophilia. This marks our evolution from a biotech research group into a biopharma company. Leveraging proprietary modification technologies, we are developing innovative biologics for hemophilia and rare coagulation disorders. Our pipeline includes four long-/ultra-lon...
Gensciences has submitted an NDA for its recombinant coagulation factor VIII-Fc fusion protein, advancing our mission to provide ?zero-bleeding? treatment for hemophilia. This marks our evolution from a biotech research group into a biopharma company. Leveraging proprietary modification technologies, we are developing innovative biologics for hemophilia and rare coagulation disorders. Our pipeline includes four long-/ultra-long-acting factors targeting hemophilia A, B, and inhibitor cases. These candidates aim to fill the gap in China?s market, improve patient access, and position us competitively worldwide.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
South of Xinxing Road, West of Guangxian Road, Nantong Economic Technolog Deve...
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

AMWC Asia-TDAC

AMWC Asia-TDAC

Not Confirmed

envelop Contact Supplier

AMWC Asia-TDAC

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty